Hyperammonemia

Source: Wikipedia, the free encyclopedia.
Hyperammonemia
Other namesHyperammonaemia
Ammonia
SpecialtyEndocrinology Edit this on Wikidata

Hyperammonemia is a

metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to brain injury and death
. It may be primary or secondary.

Ammonia is a substance that contains

enzymes acting in sequence. It is greatly exacerbated by common zinc deficiency, which raises ammonia levels further.[1]

Signs and symptoms

Complication

Hyperammonemia is one of the metabolic derangements that contribute to hepatic encephalopathy, which can cause swelling of astrocytes and stimulation of NMDA receptors in the brain.

Diagnosis

Types

Primary vs. secondary

Acquired vs. congenital

Specific types

The following list includes such examples:

Treatment

Treatment centers on limiting intake of ammonia and increasing its excretion.

Phenylbutyrate, which is the product of phenylacetate, conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Similarly, sodium benzoate reduces ammonia content in the blood by conjugating with glycine to form hippuric acid, which is rapidly excreted by the kidneys.[7] A preparation containing sodium phenylacetate and sodium benzoate is available under the trade name Ammonul
. Acidification of the intestinal lumen using lactulose can decrease ammonia levels by protonating ammonia and trapping it in the stool. This is a treatment for hepatic encephalopathy.[8]

Treatment of severe hyperammonemia (serum ammonia levels greater than 1000

μmol/L) should begin with hemodialysis if it is otherwise medically appropriate and tolerated.[5]

Urea cycle defect like Ornithine transcarbamoylase (OTC) deficiency. Multidisciplinary team (MDT) collaboration is required to optimize this advanced treatment. Simulation training might be the best training and teaching strategy to ensure MDT successful therapy.[9]

See also

References

  1. S2CID 1141979
    .
  2. ^ .
  3. ^ a b Nepal SP, Unoki T, Inoue T, Nakasato T, Naoe M, Ogawa Y, Omizu M, Kato R, Sugishita H, Oshinomi K, Morita J, Maeda Y, Shichijo T. A case of hyperammonemia in a patient with urinary tract infection and urinary retention. Urol Sci [serial online] 2020 [cited 2021 Apr 3];31:82-4. Available from: https://www.e-urol-sci.com/text.asp?2020/31/2/82/283250
  4. ^ Kenzaka T, Kato K, Kitao A, et al. Hyperammonemia in Urinary Tract Infections. PLoS One. 2015;10(8):e0136220. Published 2015 Aug 20. doi:10.1371/journal.pone.0136220
  5. ^
  6. ^ Chawla, Jasvinder (12 September 2022). "Hyperammonemia". Medscape. Retrieved 18 March 2024.
  7. ^ "Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection) clinical pharmacology - prescription drugs and medications at RxList". Archived from the original on 2008-06-16. Retrieved 2008-06-26.
  8. PMID 37820287
    .
  9. ^ Elbaba, Mostafa. "IPE Simulation Enhances the Quality of Care in Neonatal Hyperammonemia". Cureus Journal of Medical Science.

External links